New York, NY (PRWEB) October 24, 2013
Kantar Health, a leading global healthcare consulting firm, and the ISPOR Russia HTA Chapter will host a roundtable discussion on Monday, November 4, at the ISPOR (International Society for Pharmacoeconomics and Outcomes Research) 16th Annual European Congress in Dublin.
The roundtable discussion – “How can the Russian pharma industry benefit from and leverage population and patient data with local authorities?” – will focus on the role of patient-reported outcomes, expectations of HTA agencies, and the benefits of preparing patient-reported outcomes data for the industry and state. The session will be led by Mira Pavlovic, M.D., Deputy Director for Health Technology Assessment, Haute Autorité de Santé, Saint-Denise La Plane, France, EUnetHTA; participants include:
- Natalia Kolerova, Head of Market Access Oncology, RUC Region, Novartis
- Vitaly V. Omelianovskiy, M.D., Ph.D., Director, Center for HTA at the Russian Presidential Academy of National Economy and Public Administration, President of the ISPOR Russia HTA Chapter
- Tim Victor, Ph.D., Vice President of Science and Strategy, Kantar Health
- Mark Harries, Managing Director, WG Consulting
The roundtable will start at 12:15pm. Visit our website to download more information on the roundtable and speakers or to see a full list of Kantar Health’s posters. Kantar Health is a sponsor of the ISPOR 16th Annual European Congress.
About Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.
Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 700+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit http://www.kantarhealth.com.